Molecular Hydrogen on the Path to Modern Medicine
The study builds on international research into molecular hydrogen in the fields of neurology and neuroprotection and is being carried out in cooperation between Czech and Japanese experts. A key figure in the project is the internationally recognized Japanese scientist Professor Shigeo Ohta, who has devoted more than 21 years of his professional career to research on molecular hydrogen and has registered a number of patents in this field.
A Global Problem Without a Simple Solution
Dementia and neurodegenerative diseases are among the greatest challenges of modern medicine today. They affect tens of millions of people worldwide, and their impact is not only medical but also social and economic. The costs of caring for patients with dementia amount to trillions of dollars annually on a global scale and continue to rise as life expectancy increases.
This is precisely why modern medicine is increasingly focusing on early stages—phases in which it is possible to work with safe, simple, and non-invasive approaches that have the potential to improve quality of life while also meeting strict regulatory requirements. Mild cognitive impairment (MCI) is one of these key stages.
Clinical Study: Facts That Build Trust
The clinical study launched in Ostrava has been designed with maximum emphasis on expertise and transparency:
-
single-arm, single-center study
-
approximately 30 participants aged 50–80
-
duration of 6 months (3 months of inhalation, followed by 3 months of follow-up)
-
inhalation of molecular hydrogen for 1 hour, 5 times per week
-
approved by the Ethics Committee of University Hospital Ostrava and the State Institute for Drug Control (SÚKL)
The primary objective is to verify the safety of inhaling gaseous hydrogen; secondary endpoints include selected health parameters and standardized questionnaire scales.
The Story of Professor Ohta: 21 Years Devoted to One Idea
Professor Shigeo Ohta is globally regarded as the father and founder of molecular hydrogen research in biomedicine. For more than two decades, he has systematically studied its biological effects and helped transform what was once a marginal topic into a highly respected and frequently cited field of modern medicine.
“When I look back today, I see more than 21 years of life devoted to a single idea,” says Professor Ohta.
The significance of molecular hydrogen has gradually become established particularly in Japanese healthcare, where it is already used mainly in emergency medicine—for example in cases of cardiac arrest, stroke, or other critical conditions where rapid patient stabilization is essential to create space for further urgent care.
It was precisely this experience that led Japanese experts to debate the need to register hydrogen as a medicinal gas so that it could be routinely used in additional indications. In Japan, however, this process is extremely lengthy and financially demanding and could take up to ten years. On the recommendation of colleagues, Professor Ohta therefore decided to seek a path in Europe, where regulatory procedures in this area are faster and more transparent.
Why the Czech Republic and H2 Global Group?
This European path led Professor Ohta to collaborate with H2 Global Group, led by founder and CEO David Maršálek. Maršálek has been professionally engaged in molecular hydrogen for more than 14 years and has long been striving to anchor it within serious, evidence-based medicine.
“The project has so far been financed exclusively by Czech investors, including well-known personalities, physicians, scientists, lawyers, and others who are gradually joining. They want not only to support the project but also to participate in the subsequent capitalization of this significant medical breakthrough,” says David Maršálek.
“Since the COVID period, there has been unprecedented global interest in medical innovations capable of addressing the greatest medical challenges of our time. Pharmaceutical and medical technology companies are therefore actively seeking projects of this type in order to acquire them and scale them worldwide,” Maršálek adds.
Not a Product, but a Platform
The study uses a prototype of a multi-purpose hydrogen generator that was primarily developed specifically for inhalation within this clinical study. At the same time, this unique device is intended to serve as the basis for the registration of the world’s first medical device using molecular hydrogen.
However, the ambition goes further. The platform approach envisages expansion into other areas of medicine, for example through specialized applicators for the eyes, ears, limbs, or dental applications. This represents the near future of modern medicine.
“In our concept, this is not about a product, but about a path toward a MedTech platform for longevity clinics, spa medicine, and the medicine of the future. The goal is to extend healthy lifespan in humans and animals and to move hydrogen into standard therapeutic care,” says PharmDr. Milan Krajíček, Director of Research, Development, and Manufacturing at H2 Global Group.
MedTech Reality: Why Investors Seek This Stage
The history of global MedTech clearly shows a recurring pattern: the greatest value is created when clinical data, regulatory credibility, and an internationally scalable model converge. Projects at this stage often become targets for strategic partnerships or acquisitions by global pharmaceutical and technology companies.
This is precisely where H2 Global Group stands today—on the threshold of clinical and regulatory validation, with a clear vision for further expansion.
“The world faces a major problem and is searching for effective solutions, and we are convinced that we have one,” says David Maršálek. “This is not about science for science’s sake. It is about a path toward introducing a new non-invasive standard into medicine and thereby changing the lives of individuals, families, and entire healthcare systems. At a time when the incidence of neurodegenerative diseases is growing faster than care capacity, the greatest luxury is waiting—not for a ‘better moment,’ not for ‘the right subsidies,’ not until it is too late.”
“People sometimes ask me why we don’t take the standard route—European grants, banks, large investment institutions. I see it this way: these negotiations and administrative processes are often lengthy and ultimately uncertain. We have chosen to give ordinary people the opportunity to be part of this change, to participate in transforming a system that will bring new non-invasive methods into healthcare. We want to share success with those who truly need this solution,” Maršálek explains. “The standard path is slow. And given the state of today’s society, where many people need help now, we know we no longer have enough time.”
This is precisely why the project is so exceptional for investors: it is an opportunity to enter at the decisive MedTech phase—where vision becomes clinical reality, data become regulatory trust, and trust enables global scaling. It is not just an investment for financial return. It is an investment with profound societal impact and meaning. And when this journey is complete, the reward will not only be financial, but also social: the ability to say, “I was there,” when the medicine of the future began to take shape.
Public Call for Participation in the Study
A public call for volunteers has also been announced for individuals interested in participating in the study who meet the basic criteria:
age 50–80, overall good health, and a diagnosis of mild cognitive impairment up to mild or moderate dementia, preferably residing in Ostrava or the surrounding area.
Interested individuals may still apply by email: david.skoloudik@H2medical.com
Participation in this study does not guarantee any health benefit and should not be considered a substitute for standard medical treatment.
For more information about opportunities to become involved in this globally significant project, please contact the founder and CEO David Maršálek (david.marsalek@H2global.group) or David Konupčík, Director of Investor Relations (david.konupcik@H2invest.cz).
More about the company:
www.H2global.group
www.MolekularniVodik.cz
https://www.ceskenoviny.cz/pr/zpravy/2775272?h=e46f0fde2e128d43c33f9c512a3657c3